Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: results from a phase I extension trial.

@article{Richly2009CombinationOS,
  title={Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: results from a phase I extension trial.},
  author={Heike Richly and Beate S Schultheis and Irenaus A Adamietz and Petra Kupsch and Meinhard Grubert and Ralf Axel Hilger and Martin Ludwig and Erich Brendel and O. E. Christensen and Dirk Strumberg},
  journal={European journal of cancer},
  year={2009},
  volume={45 4},
  pages={579-87}
}
Sorafenib, an oral multikinase inhibitor, shows efficacy in renal cell and hepatocellular carcinoma (HCC) and is well tolerated when combined with doxorubicin in other solid tumours. Eighteen patients with inoperable HCC received doxorubicin 60 mg/m(2) IV for up to six 3-week cycles. Sorafenib 400mg bid was administered continuously starting day 4. Patients discontinuing doxorubicin were eligible for sorafenib monotherapy. The most frequent grade 3-4 drug-related adverse events were… CONTINUE READING

From This Paper

Topics from this paper.
28 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 28 extracted citations

Similar Papers

Loading similar papers…